Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Suppression of p24 antigen in sera from HIV-infected individuals with low-dose alpha-interferon and zidovudine: a pilot study.

Research output: Contribution to journalJournal articleResearch

  1. Impact of early antiretroviral treatment on sexual behaviour: a randomised comparison

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Prevalence and risk factors of prolonged QT interval and electrocardiographic abnormalities in persons living with HIV

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Primary resistance to integrase strand-transfer inhibitors in Europe

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Why START? Reflections that led to the conduct of this large long-term strategic HIV trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Risk of HIV or second syphilis infection in Danish men with newly acquired syphilis in the period 2000-2010

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
On the basis of the observations that HIV antigenaemia indicates a high risk of progression to AIDS and that zidovudine and alpha-interferon act synergistically against HIV replication in vitro, we performed a pilot trial including 12 HIV-infected asymptomatic patients with detectable p24 antigen in serum. The patients received low-dose lymphoblastoid alpha-interferon alone for 4 weeks followed by a combination of interferon and low-dose zidovudine for a further 16 weeks. The median p24 antigen level decreased significantly (P less than 0.01), the decrease being most pronounced at week 5. Decreases in haemoglobin and neutrophil counts were observed. Four patients required reduction of the zidovudine dose and three patients were transfused. In conclusion, the drug combination was capable of reducing the serum level of HIV p24 antigen and it was tolerated by the patients. Further studies are required to evaluate the clinical implications of these observations.
Translated title of the contributionSuppression of p24 antigen in sera from HIV-infected individuals with low-dose alpha-interferon and zidovudine: a pilot study.
Original languageEnglish
JournalAIDS (London, England)
Volume3
Issue number2
Pages (from-to)97-100
Number of pages4
ISSN0269-9370
Publication statusPublished - 1989

ID: 32517466